JAMA Dermatology | Brief Report

Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic

Juncal Roca-Ginés, MD; Ignacio Torres-Navarro, MD; Javier Sánchez-Arráez, MD; Carlos Abril-Pérez, MD; Oihana Sabalza-Baztán, BS-M; Sergio Pardo-Granell, PharmG; Vicent Martínez i Cózar, MD; Rafael Botella-Estrada, MD, PhD; Montserrat Évole-Buselli, MD, PhD

IMPORTANCE A novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been identified as the cause of a pandemic called *coronavirus disease 2019* (COVID-19). In this context, some associated skin diseases have been described. Cutaneous lesions referred to as *acute acro-ischemia* have been reported as a possible sign of COVID-19 in adolescents and children.

OBJECTIVE To evaluate the pathogenesis of these newly described acute acral lesions.

DESIGN, SETTING, AND PARTICIPANTS This prospective case series was conducted at La Fe University Hospital, a tertiary referral hospital in Valencia, Spain, between April 9 and April 15, 2020. Among 32 referred patients, 20 children and adolescents with new-onset inflammatory lesions did not have a diagnosis.

EXPOSURES Patients were not exposed to any drug or other intervention.

MAIN OUTCOMES AND MEASURES We performed reverse transcriptase-polymerase chain reaction for SARS-CoV-2 and a range of blood tests for possible origins of the lesions. Skin biopsies were performed in 6 patients.

RESULTS Of the 20 patients enrolled, 7 were female and 13 were male, with an age range of 1 to 18 years. Clinical findings fit into the following patterns: acral erythema (6 patients), dactylitis (4 patients), purpuric maculopapules (7 patients), and a mixed pattern (3 patients). None of the patients had remarkable hematologic or serologic abnormalities, including negative antibodies to SARS-CoV-2. Biopsies performed in 6 patients showed histologic findings characteristic of perniosis.

CONCLUSIONS AND RELEVANCE The clinical, histologic, and laboratory test results were compatible with a diagnosis of perniosis, and no evidence was found to support the implication of SARS-CoV-2 infection.

JAMA Dermatol. doi:10.1001/jamadermatol.2020.2340 Published online June 25, 2020. Editor's Note

Author Affiliations: Department of Dermatology, Hospital Universitario y Politécnico La Fe. Valencia. Spain (Roca-Ginés, Torres-Navarro, Sánchez-Arráez, Abril-Pérez, Botella-Estrada, Évole-Buselli): Department of Microbiology, Hospital Universitario v Politécnico La Fe. Valencia, Spain (Sabalza-Baztán, Pardo-Granell); Department of Pathology, Hospital Universitario y Politécnico La Fe, Valencia, Spain (Martínez i Cózar); Department of Medicine, School of Medicine, Universitat de València, Valencia, Spain (Botella-Estrada)

Corresponding Author: Ignacio Torres-Navarro, Department of Dermatology, Hospital Universitario y Politécnico la Fe, 106 Fernando Abril Martorell Ave, Valencia 46026, Spain (nacho.torres.navarro@gmail.com).

t the end of 2019, a novel coronavirus called *severe acute* respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of an outbreak of pneumonia and severe acute respiratory syndrome in Wuhan, China.¹ On January 30, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) a public health emergency of international concern.² Although SARS-CoV-2 infection can affect individuals of any age, severe illness is uncommon in children.

Recently, possible COVID-19-related skin changes have been described: mostly urticaria, drug-related eruptions, and chickenpox-like vesicles.³ In addition, cutaneous lesions referred to as *acute acro-ischemia* have been reported as a possible sign of SARS-CoV-2 infection in adolescents and children.⁴ In this article, we report an outbreak of acral skin lesions observed between April 9 and April 15, 2020.

jamadermatology.com

Methods

A prospective case series was performed at La Fe University Hospital, Valencia, Spain, to assess the clinical and etiologic features of children and adolescents with acute acroischemia. Among 32 patients referred for acral lesions between April 9 and April 15, 2020, we included 20 who presented with new-onset acral inflammatory lesions without an obvious diagnosis of recognizable cause.

Each patient underwent a complete blood cell count; biochemistry tests for liver and kidney function, erythrocyte sedimentation rate, and levels of ferritin, lactate dehydrogenase, and C-reactive protein; coagulation tests, including levels of D-dimer, cryoglobulins, and proteins C and S; urine sediment examination; autoimmunity tests for antinuclear antibodies (enzyme-linked immunosorbent assay [ELISA] and indirect immunofluorescence assay), antineutrophil cytoplasmic antibodies, antiphospholipid antibodies (lupus anticoagulant, anti- β_2 -glycoprotein, anticardiolipin antibody), C3, C4, and interleukin 6; serologic tests for enterovirus, Epstein-Barr virus, human herpesvirus 6, parvovirus B19, mycoplasma, rubella, and measles; tests for immunoglobulin (Ig) G, IgM, and IgA (COVID-19 ELISA Kit, Vircell; sensitivity and specificity for IgG and IgM + IgA joint detection of 70% and 98%); and reverse transcriptase-polymerase chain reaction (RT-PCR) by nasopharyngeal swab for SARS-CoV-2 (Viasure SARS-CoV-2 Real Time PCR Detection Kit, CerTest Biotec; detection limit \geq 10 RNA copies per reaction for the *ORF1ab* and *N* genes).

This study was approved by the institutional review board of La Fe University Hospital, and written informed consent for each procedure and for publication was obtained from all patients or their families.

Results

Twenty patients were included in this study, 13 of whom were male. Main characteristics of the patients are depicted in the **Table**.

No patient had any clinical symptoms (fever, fatigue, dry cough, anorexia, myalgia, dyspnea, sputum, headache, sore throat, smell or taste disorders, or rhinorrhea) suspected to be COVID-19-related.^{1,2,5} Similarly, no co-inhabitant showed any symptoms. Ten of 20 patients lived with relatives older than 50 years (6 of whom were older than 80 years). The mean (SD) age of the patients was 12.3 (4.3) years, and no patient was older than 18 years. Nine of them (45%) had a history of vascular reactive disease of the hands (Raynaud phenomenon or perniosis). Only patient 8 had a history of connective tissue disease (systemic lupus erythematosus). None of them reported previous drug intake except for patient 18, who had taken a single dose of 500 mg of acetaminophen 2 weeks before, and patient 10, who had started treatment for anemia with ferric sulfate 1 month before. Fifteen (75%) reported walking barefoot around the house during the quarantine. Of all patients, only 2 lived in a home equipped with a heating system. No abnormal test results were found in any patient except for patient 3 and patient 8, who had positive results for antinuclear antibodies (titers of 1/160 and 1/1280, respectively).

Dermatologic findings were classified into the following groups based on skin pattern: periungual erythema; inflammation of 1 or more fingers with occasional whitish areas, which we have called *dactylitis*; and purpuric maculopapules with occasional blisters. In some patients, we observed a mix of lesions. Acral erythema was found in 6 (30%) of the cases (**Figure 1**A), dactylitis in 4 (20%) (Figure 1B), purpuric maculopapules in 7 (35%) (Figure 1C), and a mixed pattern in 3 (15%) (Figure 1D).

We obtained 6 skin biopsy specimens from 6 different patients. Results are presented in the Table and **Figure 2**. In all patients, results of serologic and viral testing were negative for SARS-CoV-2 as well as other viruses.

E2

Key Points

Question What is the association between acute acral lesions and coronavirus disease 2019 (COVID-19) in children and adolescents?

Findings In this case series of 20 patients aged 1 to 18 years with new-onset acral inflammatory lesions, all lacked systemic manifestations of COVID-19. Both reverse transcriptasepolymerase chain reaction and serologic test results were negative for severe acute respiratory syndrome coronavirus 2.

Meaning An association between acral skin disease and COVID-19 has yet to be proved.

Discussion

On March 14, 2020, a state of emergency was declared in Spain, and strict stay-at-home rules were imposed. Citizens were alerted to a series of signs and symptoms to detect early SARS-CoV-2 infection. Reports of diverse cutaneous lesions as possible symptoms of COVID-19 have led to an increase in visits to our hospital for any of these manifestations.⁴ However, apart from temporal coexistence, the involvement of COVID-19 in the development of these lesions has not been proved so far.

In this article, we report a series of 20 cases of cutaneous lesions classifiable on the clinical spectrum of perniosis. Regarding histologic features, it is worth noting that there is bias because 5 of 6 biopsies were performed in patients with more severe lesions. Nevertheless, the histologic findings in all of them were characteristic of chilblains, confirming the clinical impression.⁶

When evaluating the pathogenesis of these lesions, several possibilities emerge. Both our cases and others reported in the literature have developed in a short space of time, generally with an onset in the second to third week of the pandemic.⁷⁻¹² Some of the cases that have been described occurred in patients with SARS-CoV-2 infection demonstrated by RT-PCR or in symptomatic patients, but there are also a large number of patients, similar to ours, in whom the presence of the virus could not be demonstrated by RT-PCR, the serologic test results were negative, or the patients were asymptomatic.⁷⁻¹¹

At least 3 different scenarios may be considered to explain the abrupt appearance, during the peak of the pandemic, of these characteristic lesions in a group of SARS-CoV-2-negative patients. One possibility is that the patients were in a very early stage of the disease, which would explain the negativity of PCR and serologic test results.⁸ This seems to us the least probable explanation, given that the mean (SD) duration of the disease before consultation in our series was 13.25 (8.11) days and we conducted follow-up in all patients for 4 additional weeks.

The second alternative is that acrocyanosis and perniosis were a subacute manifestation of the infection, in which patients no longer had detectable viral particles.⁸⁻¹² Additionally, in situations in which the viral inoculum was small, it is conceivable that the RT-PCR results were negative, patients did not develop other symptoms, and the serologic

Mutuality Mutuality Controlutions Controlutions Mutuality Controlutions	Table. Main Characteristics of the Patients ^a	in Charact										
d Sintexions Endemalchanges Demalchanges Demalchanges Feet AE Satreen KAA Endothelial swelling Hands D NP No Hands D NP NP Hands D NP NP Hands and feet MP NP NP Hands and feet D NP NP Hands and feet D NP NP Hands and feet D NP NP Feet D NP NP NP Feet D NP NP NP Feet NP NP NP NP Hands and feet	Patient			Wears shoes	Heat in	Co-inhabitants with similar	Disease duration hefore	l ocation of	Tvne of	Histopathologic finding	S	
Fet AE Sattered NGA Endotherial swelling Niid VC Niid VC Niid VC Niid VC Hands D NP NP Hands D NP NP Hands D NP NP Hands D NP NP Hands and feet D NP NP Hands and feet D NP NP Feet D NP NP Feet D NP NP Feet NP NP NP Feet NP NP NP Feet NP NP NP Feet NP NP NP Notesta edema NP NP NP Feet NP NP NP Hands and feet NP NP NP Feet NP NP NP Feet NP NP NP Hands and feet	No.	Sex	PAVR	at home	home	symptoms	consultation, d	skin lesions	acral lesions	Epidermal changes	Dermal changes	Infiltrate allocation
Spongiosis Mid VC Mid VC Hands and feet N N Hondsand feet N N Feet N N Hands and feet N N	1	Σ	Yes	Yes	No	No	7	Feet	AE	Scattered NKA	Endothelial swelling	Papillary dermis
Mid VC Mid VC Hands and feet NP NP Hands and feet NP NP Hands and feet NP NP										Spongiosis		PV
Hands D NP NP Hands and feet M(C), M(P) NP NP Hands and feet N NP NP Hands and feet N Spongiosis Lindhordial swelling Feet NP NP NP Feet D NP NP Feet NP NP NP Hands and feet AP NP NP Feet NP NP NP Hands and feet AP NP NP Feet N										Mild VC		PE
Hands and feet MP (D, PMP) NP NP Hands and feet D NP NP NP Hands and feet D NP NP NP Hands and feet D NP NP NP Feet D NP NP NP Feet D NP NP NP Feet NP NP NP NP Hands and feet AP NP NP NP Feet NP NP NP NP Hands and feet AP N	2	ц	Yes	No	No	Yes	30	Hands	D	NP	NP	NP
Hands and feet D NP NP Feet PMP Abundant N(A) Endothelial sveiling Feet PMP Sever VC Fibrin deposition Feet D NP Moderate dema Feet NP NP Moderate dema Feet NP NP NP Hands and feet NP NP NP Feet NP NP NP Hands and feet NP NP NP Feet NP NP NP Hands and feet NP NP NP Feet NP NP NP Hands and feet NP NP Feet NP NP Hands and fee	m	ш	Yes	Yes	No	No	6	Hands and feet	MP (D, PMP)	NP	NP	NP
Fet Mundant NLA Endothelial swelling Rendom Spongiosis Lymphocytic vasculitis Fet D N Moderate dema Fet D N Moderate dema Fet D N Moderate dema Fet D N N Moderate dema Fet N N N N Mid NG N N N N Fet N N N N Hands and fet N N N N Fet N N N N Fet N N N<	4	Σ	Yes	Yes	No	No	26	Hands and feet	D	NP	NP	NP
Spongiosis Lymphocytic vascutitis Sever VC Elbin deposition Fet D NP Fet D NP Fet D NP Fet D NP Fet NP NP Hands and fet NP NP Fet NP NP Fet NP NP Fet NP NP Hands and fet NP NP Fet NP NP Hands and fet NP NP Fet NP NP Hands and fet NP NP Fet NP NP	5	Σ	Yes	Yes	No	No	21	Feet	PMP	Abundant NKA	Endothelial swelling	Papillary dermis
Sever VC Fibrin deposition Fet D NP Fet D NP Fet D NP Fet D NP Fet NP Songiosis Fet NP Songiosis Fet NP Songiosis Fet NP NP Hands and fet NP <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Spongiosis</td><td>Lymphocytic vasculitis</td><td>PV</td></td<>										Spongiosis	Lymphocytic vasculitis	PV
Moderate defination of the control o										Severe VC	Fibrin deposition	PE
Fet D NP NP Fet D NP NP NP Fet PMP Abundant N(A) Endothelial swelling Spongiosis Lymphocytic vascuitis Fet PMP NP Noderate edema Noderate edema Noderate edema Fet MP NP NP NP NP Fet MP NP NP NP Fet MP NP NP NP Fet MP NP NP NP Hands and feet AE NP NP NP Hands and feet											Moderate edema	
Feet D NP NP Feet PMP Abundant N(A) Endothelial swelling Spongiosis Spongiosis Lymphocytic vasculitis Feet PMP NP Noderate edema Feet MP NP NP Feet MP NP NP Feet PMP NP NP Feet PMP NP NP Hands and feet AE NP NP Feet PMP NP NP Hands and feet AE NP NP Feet NP NP NP Feet NP NP NP Hands and feet AE NP NP Feet NP NP NP Hands and feet NP NP Feet NP NP Hands and feet AE NP Hands and feet NP NP Feet NP NP Hands and feet NP NP Hands and feet NP NP Hands and feet NP NP Feet NP NP Hands and feet NP Hands and feet <td>9</td> <td>ц</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> <td>10</td> <td>Feet</td> <td>D</td> <td>NP</td> <td>NP</td> <td>NP</td>	9	ц	Yes	Yes	No	No	10	Feet	D	NP	NP	NP
Fet PMP Abundant NKA Endothelial swelling Spongiosis Spongiosis Lymphocytic vasculitis Sever VC Fibrin deposition Fet MP NP Fet PMP NP Fet PMP NP Hands and fet AE NP Fet MP NP Hands and fet AE NP Fet NP NP Hands and fet AE NP Fet MP NP Hands and fet AE NP Fet MP NP Fet NP NP Hands and fet AE NP Fet PMP NP Hands and fet AE NP Fet NP NP Hands and fet AE NP Hands and fet AE NP Fet NP NP Hands and fet AE NP Hands and fet AE NP Fet NP NP	7	Ø	No	Yes	No	No	10	Feet	D	NP	NP	NP
Spongiosis Lymphocytic vascuitis Severe VC Fibrin deposition Feet MP Moderate edema Feet MP NP NP Hands and feet AE NP NP Hands and feet NP NP NP Feet MP NP NP Hands and feet AE NP NP Feet MP NP NP Hands and feet AE NP NP Hands and feet AE NP NP Hands and feet NP NP NP Hands and feet AE NP NP Hands and feet NP NP NP Hands and feet AE NP NP Hands and feet AE NP <td>8</td> <td>ц</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> <td>10</td> <td>Feet</td> <td>PMP</td> <td>Abundant NKA</td> <td>Endothelial swelling</td> <td>Papillary dermis</td>	8	ц	Yes	Yes	No	No	10	Feet	PMP	Abundant NKA	Endothelial swelling	Papillary dermis
Sever VC Fibrin deposition Feet NM NM Feet NP NP Hands and feet NP NP Feet NP NP Hands and feet NP NP Feet NP NP Hands and feet NP NP Hands NP NP Feet NP NP Hands NP NP <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Spongiosis</td><td>Lymphocytic vasculitis</td><td>PV</td></t<>										Spongiosis	Lymphocytic vasculitis	PV
Moderate defena Fete Mup NP Fete Mp NP NP Fete Mp NP NP Fete Mp NP NP Fete Mp Mid VC Demat thrombi Fete NP NP NP Hands and fete AE NP NP Hands and fete AE NP NP Fete MP NP NP Fete MP NP NP Fete MP NP NP Fete NP NP NP Hands and fete NP NP NP Hands and fete NP NP NP Hands NP NP NP Hands and fete NP NP NP </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Severe VC</td> <td>Fibrin deposition</td> <td>PE</td>										Severe VC	Fibrin deposition	PE
Feet PMP NP NP Feet MP NP NP Feet PMP MId NKA Endothelial swelling Feet PMP NId NKA Endothelial swelling Feet PMP NP NP Hands and feet AE NP NP Feet AE NP NP Feet MP NP NP Feet MP NP NP Feet MP NP NP Feet MP NP NP Hands and feet NP NP NP											Moderate edema	
Fet MP NP NP Fet PMP MId N(A Endothelial swelling Fet PMP MId N(A Endothelial swelling Fet PMP NP Demal thrombi Hands and feet AE NP NP Feet AE NP NP Feet MP NP NP Feet MP NP NP Feet PMP NP NP Hands and feet AE NP NP Feet PMP NP NP Hands and feet NP NP NP Feet PMP NP NP Severe VC NP NP Feet NP	6	Σ	No	Yes	No	Yes	17	Feet	PMP	NP	NP	NP
Feet PMP Mid NKA Endothelial swelling Feet PmP PmP Pmat thrombi Hands and feet R N N Hands and feet AE NP NP Hands and feet NP NP NP Feet MP NP NP Feet MP NP NP Feet MP NP NP Hands and feet R NP NP Hands and feet NP NP NP Feet NP NP NP Feet PMP NP NP Feet PMP NP NP Feet PM NP NP Feet NP NP NP Secret VC NP NP Feet NP NP Secret VC NP NP	10	Ŀ	No	No	No	Yes	7	Feet	MP	NP	NP	NP
Spongiosis Demal thrombi Mid VC Mid VC Feet NP NP Hands and feet AE NP Feet AE NP Feet MP NP Hands and feet NP NP Feet NP NP Hands and feet NP NP Spongiosis Find heposition Mid VC Dermal thrombi	11	Σ	No	Yes	No	No	10	Feet	PMP	Mild NKA	Endothelial swelling	Papillary dermis
Mid VC Feet PMP NP Hands and feet AE NP NP Hands and feet AE NP NP Feet AE NP NP Feet AE NP NP Feet MP NP NP Feet MP NP NP Hands and feet NP NP NP Feet NP NP NP Feet PMP NP NP Feet PMP NP NP Spongiosis Find heposition NP Mid VC Dermal thrombi NP *Aesranet for NIXA Permal thrombi NP										Spongiosis	Dermal thrombi	PV
Fet PMP NP NP Hands and feet AE NP NP Feet AE NP NP Feet MP NP NP Feet MP NP NP Feet MP NP NP Feet MP NP NP Feet PMP MId NKA Endothelial swelling Feet NP Spongiosis Lymphocytic vasculitis Hands and feet AE NP NP Hands and feet AE NP NP Hands and feet AE NP NP Feet AE NP NP Feet PMP NP NP Feet PMP NP NP Feet PMP Abundant NKA Endothelial swelling Spongiosis NP NP NP										Mild VC		PE
Hands and feet AE NP NP Feet AE NP NP Feet MP NP NP Feet MP NP NP Feet MP NP NP Feet MP NP NP Feet PMP MId NKA Endothelial swelling Feet NP Spongiosis Lymphocytic vasculitis Hands and feet AE NP NP Hands AE NP NP Hands AE NP NP Feet AE NP NP Feet PMP NP NP Feet PMP NP NP Feet PMP NP NP Spongiosis Endothelial swelling Spongiosis Endothelial swelling	12	Σ	No	Yes	No	No	30	Feet	PMP	NP	NP	NP
Feet AE NP NP Feet MP NP NP Feet MP MId NKA Endothelial swelling Feet PMP Spongiosis Lymphocytic vasculitis Andread AE NP NP Hands AE NP NP Hands AE NP NP Feet AE NP NP ABundant NKA Endothelial swelling Spongiosis Elprin deposition	13	M	No	No	Yes	No	10	Hands and feet	AE	NP	NP	NP
Feet MP NP Feet PMP Mid NKA Endothelial swelling Feet PMP Mid NKA Endothelial swelling About State Spongiosis Lymphocytic vasculitis Bands and feet AE NP NP Hands AE NP NP Hands AE NP NP Feet AE NP NP Feet PMP Andant NKA Endothelial swelling Feet PMP NP NP Feet PMP Andant NKA Endothelial swelling PASTATHAT Andant NKA Endothelial swelling	14	Σ	No	Yes	No	No	e	Feet	AE	NP	NP	NP
Feet PMP Mid NKA Endothelial swelling Spongiosis Enpohocytic vasculitis Hands AE NP Hands AE NP Hands AE NP Hands AE NP Feet AE NP Feet PMP Abundant NKA Feet PMP Abundant NKA Feet PMP Abundant NKA Assertant Abunda Abundant NKA Endothelial swelling	15	Σ	No	No	No	Yes	7	Feet	MP	NP	NP	NP
Spongiosis Lymphocytic vascuitis Severe VC Moderate defma Hands and feet AE NP Hands and feet NP NP Hands AE NP NP Hands AE NP NP Feet AE NP NP Feet PMP Abundant NKA Endothelia swelling Feet PMP Abundant NKA Endothelia swelling Spongiosis Fibrin deposition Mid VC Dermal thrombi	16	Σ	No	Yes	Yes	No	7	Feet	PMP	Mild NKA	Endothelial swelling	Papillary dermis
Sever VC Moderate edema Hands and feet AE NP Hands AE NP Hands AE NP Feet AE NP Feet PMP Abundant NKA Endothelial swelling Feet PMP Abundant NKA Endothelial swelling PARA Abundant NKA Endothelial swelling Abara Abundant NKA Endothelial swelling										Spongiosis	Lymphocytic vasculitis	PV
Hands and feet AE NP NP Hands AE NP NP Feet AE NP NP Feet PMP Abundant NKA Endothelial swelling Feet PMP Abundant NKA Endothelial swelling Abundant NKA Abundant NKA Endothelial swelling Abundant NKA Abundant NKA Endothelial swelling										Severe VC	Moderate edema	PE
Hands AE NP NP Feet AE NP NP Feet PMP Abundant NKA Endothelial swelling Feet PMP Abundant NKA Endothelial swelling Abundant NKA Abundant NKA Endothelial swelling Abundant NKA Abundant NKA Endothelial swelling Abundant NKA Abundant NKA Endothelial swelling	17	ш	Yes	Yes	No	No	4	Hands and feet	AE	NP	NP	NP
Feet AE NP NP Feet PMP Abundant NKA Endothelial swelling Spongiosis Endothelial swelling Mid VC Dermal thrombi	18	ц	No	No	No	Yes	14	Hands	AE	NP	NP	NP
Feet PMP Abundant NKA Endothelial swelling Spongiosis Fibrin deposition Mild VC Dermal thrombi	19	M	Yes	Yes	No	Yes	14	Feet	AE	NP	NP	NP
Spongiosis Fibrin deposition Mild VC Dermal thrombi ^a Ages ranged from 1 to 18 years. Provide the state of the state	20	Σ	No	Yes	No	No	19	Feet	PMP	Abundant NKA	Endothelial swelling	Papillary dermis
Mild VC Dermal thrombi ^a Ages ranged from 1 to 18 years.										Spongiosis	Fibrin deposition	PV
										Mild VC	Dermal thrombi	PE
PV, perivascular; VC, vacuolar changes.	Abbreviatic performed;	ons: AE, ac. PAVR, pre	ral erythema; vious acral vas	D, dactylitis; MP, m scular reactivity: PE	iixed pattern; ⁿ E, perieccrine;	NKA, necrotic keratir PMP, purpuric macu	rocytes; NP, not lopapules:	^a Ages rangec	d from 1 to 18 years.			
	PV, perivas	cular; VC, v	/acuolar chang	şes.	-		-					

jamadermatology.com

Figure 1. Details of the Clinical Spectrum

B Dactylitis pattern





C Maculopapular purpuric pattern



D Mixed pattern



A, Acral erythema pattern on the dorsal side of the toes. B, Inflammation of 1 toe showing a dactylitis pattern. C, Moderate vasculitic-like lesions on the feet demonstrating a maculopapular purpuric pattern. D, Mixed pattern composed of dactylitis and purpuric maculopapules.

response was of low intensity and not detectable with the tests currently available. Serologic responses have been shown to be lower in young individuals than in older ones.¹³ In this scenario, the only manifestations of COVID-19 could be endotheliitis and a facility for thrombosis in the distal small vessels of the extremities.^{8,9,14} Entotheliitis and


thrombosis have been described in patients with severe COVID-19 with previous endothelial damage and cardiovascular comorbidity (eg, diabetes, hypertension, obesity).^{14,15} However, the absence of those risk factors and the unaltered results of the coagulation tests performed in our patients do not support this explanation.

A Acral erythema pattern

Figure 2. Main Histologic Features



B Original magnification ×200



A, Acral skin with moderate edema in the papillary dermis, perivascular/ perieccrine lymphohistiocytic infiltrate, and lymphocytic vasculitis (hematoxylin-eosin). B, Severe perieccrine and deep perivascular infiltrate. Notice the presence of lymphocytic vasculitis as well as fibrin deposition in the vessel walls (hematoxylin-eosin).

Finally, a third possibility, which is not supported by the results of all of the complementary examinations carried out in our patients, is that these skin lesions are not induced by the virus but by the quarantine state itself. Accordingly, this quarantine perniosis appeared mainly in children isolated in houses that were not well suited for individuals who spent long periods barefoot or only wearing socks and with very little physical activity.

Limitations

This study was carried out in a short period and with patients from a single center. Furthermore, there is still limited knowl-

ARTICLE INFORMATION

Accepted for Publication: May 15, 2020.

Published Online: June 25, 2020. doi:10.1001/jamadermatol.2020.2340

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Roca-Ginés J et al. *JAMA Dermatology*.

Author Contributions:Drs Torres-Navarro and Botella-Estrada had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Botella-Estrada and Évole-Buselli contributed equally.

Concept and design: Roca-Ginés, Torres-Navarro, Sánchez-Arráez, Abril-Pérez, Botella-Estrada, Évole-Buselli.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Roca-Ginés, Torres-Navarro, Sánchez-Arráez, Abril-Pérez, Martínez i Cózar, Botella-Estrada, Évole-Buselli. Critical revision of the manuscript for important intellectual content: Roca-Ginés, Torres-Navarro, Sánchez-Arráez, Abril-Pérez, Sabalza-Baztán, Pardo-Granell, Botella-Estrada, Évole-Buselli. Statistical analysis: Roca-Ginés, Torres-Navarro. Obtained funding: Torres-Navarro. Administrative, technical, or material support: Roca-Ginés, Torres-Navarro, Abril-Pérez, Sabalza-Baztán, Pardo-Granell. *Supervision:* Roca-Ginés, Torres-Navarro, Botella-Estrada, Évole-Buselli. *Other (diagnosis pathology):*Martínez i Cózar.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was funded by the Department of Dermatology of La Fe University Hospital.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the patients and their families for granting permission to publish this information. We also thank María Dolores Gómez-Ruiz, PhD, and Carmina Sos-Lloret, MD, from the Department of Microbiology, Hospital Universitario y Politécnico La Fe, for their support. They did not receive compensation for this work.

REFERENCES

1. Guan W-J, Ni Z-Y, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical

edge regarding the clinical manifestations of and detection methods for SARS-CoV-2.

Conclusions

In this case series of 20 children and adolescents, a relationship between acute acral skin changes and COVID-19 could not be demonstrated. Other studies with improved microbiologic tests or molecular techniques aimed at demonstrating the presence of SARS-CoV-2 in the skin may help to clarify this problem.

> characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032

2. McIntosh K. Coronavirus disease 2019 (COVID-19): epidemiology, virology, clinical features, diagnosis, and prevention. UpToDate website. https://www.uptodate.com/contents/ coronavirus-disease-2019-covid-19-epidemiologyvirology-and-prevention. Updated June 9, 2020. Accessed June 10, 2020.

3. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol.* 2020;34(5):e212-e213. doi:10.1111/jdv.16387

4. Mazzotta F, Troccoli T. Acute acro-ischemia in the child at the time of COVID-19. *Dermatologia Pediatr Bari*. https://www.fip-ifp.org/wp-content/ uploads/2020/04/acroischemia-ENG.pdf. Accessed June 10, 2020.

5. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol*. Published online April 6, 2020. doi:10.1007/s00405-020-05965-1

6. Cribier B, Djeridi N, Peltre B, Grosshans E. A histologic and immunohistochemical study of

jamadermatology.com

chilblains. *J Am Acad Dermatol*. 2001;45(6):924-929. doi:10.1067/mjd.2001.117861

7. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. *J Am Acad Dermatol*. Published online April 24, 2020. doi:10.1016/j.jaad.2020.04.093

8. Romaní J, Baselga E, Mitjà O, et al. Chillblains and acral purpuric lesions in Spain during Covid confinement: retrospective analysis of 12 cases [in Spanish]. *Actas Dermosifiliogr*. Published online April 22, 2020.

9. Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in the time of COVID-19. *J Eur Acad Dermatology Venereol.* Published online April 24, 2020. doi:10.1111/jdv.16533 **10**. Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. *J Eur Acad Dermatol Venereol*. Published online April 24, 2020. doi:10.1111/jdv.16526

11. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 pandemic. *Int J Dermatol.* 2020;59(6):739-743. doi:10.1111/jid.14937

12. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on "Cutaneous manifestations in COVID-19: a first perspective " by Recalcati S. *J Eur Acad Dermatol Venereol.* Published online April 21, 2020. doi:10.1111/ jdv.16519

13. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19

recovered patient cohort and their implications. *SSRN Electron J*. Published online April 9, 2020. doi:10.2139/ssrn.3566211

14. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Transl Res.* Published online April 15, 2020. doi:10.1016/j.trsl. 2020.04.007

15. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736 (20)30937-5